These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24601914)

  • 1. Elevated serum thymus and activation-regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS).
    Ogawa K; Morito H; Hasegawa A; Miyagawa F; Kobayashi N; Watanabe H; Sueki H; Tohyama M; Hashimoto K; Kano Y; Shiohara T; Ito K; Fujita H; Aihara M; Asada H
    Br J Dermatol; 2014 Aug; 171(2):425-7. PubMed ID: 24601914
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
    Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
    J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.
    Watanabe H
    J Immunol Res; 2018; 2018():5163129. PubMed ID: 29744372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF-α as a useful predictor of human herpesvirus-6 reactivation and indicator of the disease process in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS).
    Uno H; Kabashima K; Tohyama M; Watanabe T; Hashimoto K; Iijima M; Sueki H; Watanabe H
    J Dermatol Sci; 2014 May; 74(2):177-9. PubMed ID: 24517870
    [No Abstract]   [Full Text] [Related]  

  • 5. Occupational trichloroethylene hypersensitivity syndrome: human herpesvirus 6 reactivation and rash phenotypes.
    Kamijima M; Wang H; Yamanoshita O; Ito Y; Xia L; Yanagiba Y; Chen C; Okamura A; Huang Z; Qiu X; Song X; Cai T; Liu L; Ge Y; Deng Y; Naito H; Yoshikawa T; Tohyama M; Li L; Huang H; Nakajima T
    J Dermatol Sci; 2013 Dec; 72(3):218-24. PubMed ID: 23928230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome.
    Nakamura-Nishimura Y; Miyagawa F; Miyashita K; Ommori R; Azukizawa H; Asada H
    Br J Dermatol; 2018 Jun; 178(6):1430-1432. PubMed ID: 29150836
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions.
    Komatsu-Fujii T; Kaneko S; Chinuki Y; Suyama Y; Ohta M; Niihara H; Morita E
    Allergol Int; 2017 Jan; 66(1):116-122. PubMed ID: 27497618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to lamotrigine differs from that due to other drugs.
    Tashiro Y; Azukizawa H; Asada H; Niihara H; Morita E; Yamauchi T; Mizukawa Y; Kusakabe Y; Numazawa S; Izumi M; Sueki H; Watanabe H
    J Dermatol; 2019 Mar; 46(3):226-233. PubMed ID: 30663091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome.
    Tohyama M; Hashimoto K; Yasukawa M; Kimura H; Horikawa T; Nakajima K; Urano Y; Matsumoto K; Iijima M; Shear NH
    Br J Dermatol; 2007 Nov; 157(5):934-40. PubMed ID: 17854362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR).
    Kano Y; Tohyama M; Aihara M; Matsukura S; Watanabe H; Sueki H; Iijima M; Morita E; Niihara H; Asada H; Kabashima K; Azukizawa H; Hashizume H; Nagao K; Takahashi H; Abe R; Sotozono C; Kurosawa M; Aoyama Y; Chu CY; Chung WH; Shiohara T
    J Dermatol; 2015 Mar; 42(3):276-82. PubMed ID: 25623158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.
    Tohyama M; Hashimoto K; Oda F; Namba C; Sayama K
    J Dermatol; 2020 May; 47(5):476-482. PubMed ID: 32162382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS).
    Miyagawa F; Asada H
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.
    Mitsui Y; Shinkuma S; Nakamura-Nishimura Y; Ommori R; Ogawa K; Miyagawa F; Mori Y; Tohyama M; Asada H
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):558-565.e4. PubMed ID: 34757063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report of drug rash with eosinophilia and systemic symptoms demonstrating human herpesvirus-6 reactivation.
    Ferrero NA; Pearson KC; Zedek DC; Morrell DS
    Pediatr Dermatol; 2013; 30(5):608-13. PubMed ID: 24016284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human herpesvirus 6 lymphadenitis in drug rash with eosinophilia and systemic symptoms syndrome: a lymphoma mimic.
    Johnson S; Mathews S; Hudnall SD
    Histopathology; 2017 Jun; 70(7):1166-1170. PubMed ID: 28008656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression profile of Th1/Th2-associated chemokines characterizes Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) as distinct entities.
    Miyagawa F; Hasegawa A; Imoto K; Ogawa K; Kobayashi N; Ito K; Fujita H; Aihara M; Watanabe H; Sueki H; Tohyama M; Asada H
    Eur J Dermatol; 2015; 25(1):87-9. PubMed ID: 25547780
    [No Abstract]   [Full Text] [Related]  

  • 17. Reactivation of Human Herpes Virus-6 in the Renal Tissue of a Patient with Drug-induced Hypersensitivity Syndrome/Drug Rash with Eosinophilia and Systemic Symptoms (DIHS/DRESS).
    Hagiya H; Iwamuro M; Tanaka T; Hasegawa K; Hanayama Y; Kimura M; Otsuka F
    Intern Med; 2016; 55(13):1769-74. PubMed ID: 27374681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution.
    Ushigome Y; Kano Y; Ishida T; Hirahara K; Shiohara T
    J Am Acad Dermatol; 2013 May; 68(5):721-8. PubMed ID: 23182063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of Human Herpesvirus 6 Reactivation in Drug Rash With Eosinophilia and Systemic Symptoms.
    Zhu H; Komaroff AL; Ren V
    JAMA Dermatol; 2024 Jun; 160(6):687. PubMed ID: 38691374
    [No Abstract]   [Full Text] [Related]  

  • 20. The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation.
    Komatsu-Fujii T; Chinuki Y; Niihara H; Hayashida K; Ohta M; Okazaki R; Kaneko S; Morita E
    Allergol Int; 2018 Jan; 67(1):90-95. PubMed ID: 28648978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.